The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy

Completed

• Conditions: Non-small Cell Lung Cancer

• Registration Number: NCT02135679
• Lead Sponsor: Abramson Cancer Center at Penn Medicine

Brief Summary

CTC levels collected pre-surgery will be correlated with pathological samples.

Detailed Description

Patients with NSCLC who undergo radiation as part of a definitive course of treatment will be enrolled. Blood collections will be obtained before, during, and after radiotherapy. We will collect demographic and treatment data and explore \& describe the pattern of CTC detection in all patients

Study Timeline

• Study Start: 2012-09
• Study First Submitted: 2014-05-02
• Study First Submitted QC: 2014-05-08
• Study First Posted: 2014-05-12
• Primary Completion: 2019-12
• Study Completion: 2021-12
• Results First Submitted: 2024-04-10
• Results First Submitted QC: 2024-09-30
• Results First Posted: 2024-10-08
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-04
• Last Update Posted: 2024-11-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 204

Inclusion Criteria

• Patients with biopsy-proven NSCLC who are undergoing definitive radiotherapy as a part of their treatment regimen.
• Age 18 or older
• Signed informed consent
• Patients who are incapable of providing informed consent are excluded from participating in this study.

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To Describe the Pattern of CTCs Before and After Definitive Radiotherapy for Each Treatment Stratum	24 months	The pattern of CTCs before and after definitive radiotherapy for each treatment stratum. CTC counts per mL before and after definitive radiotherapy.

Trial Locations

Locations (1)

Abramson Cancer Center of the University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States